share_log

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.40%)

bluebird bio | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.40%)

bluebird bio | SC 13G/A：超過5%持股股東披露文件(修正)-The Vanguard Group(5.40%)
美股SEC公告 ·  2024/11/05 02:35

Moomoo AI 已提取核心訊息

The Vanguard Group has filed an amended Schedule 13G with the Securities and Exchange Commission (SEC), indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. This filing, made under Rule 13d-1(b), shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The filing indicates that The Vanguard Group's clients, including registered investment companies and other managed accounts, have the right to receive dividends or proceeds from the sale of these securities. The Vanguard Group, based in Pennsylvania, is a major investment adviser and reports no single client holding more than 5% of the interest in the reported securities.
The Vanguard Group has filed an amended Schedule 13G with the Securities and Exchange Commission (SEC), indicating a change in their holdings of bluebird bio, Inc. common stock. As of September 30, 2024, The Vanguard Group reported beneficial ownership of 10,474,007 shares of bluebird bio, which represents 5.40% of the company's class of common stock. This filing, made under Rule 13d-1(b), shows that The Vanguard Group has shared voting power over 87,543 shares and sole dispositive power over 10,330,825 shares, with an additional shared dispositive power over 143,182 shares. The filing indicates that The Vanguard Group's clients, including registered investment companies and other managed accounts, have the right to receive dividends or proceeds from the sale of these securities. The Vanguard Group, based in Pennsylvania, is a major investment adviser and reports no single client holding more than 5% of the interest in the reported securities.
Vanguard集團已向證券交易委員會(SEC)提交了修訂後的13G日程表，表明他們持有bluebird bio公司的普通股份發生了變化。截至2024年9月30日，Vanguard集團報告擁有bluebird bio公司的10,474,007股股份，佔公司普通股類別的5.40%。根據13d-1(b)規則提交的此申報顯示，Vanguard集團共享87,543股的表決權，獨立行使對10,330,825股的處置權，並額外共享143,182股的處置權。該申報顯示，Vanguard集團的客戶，包括註冊投資公司和其他託管帳戶，有權收取這些證券的分紅或出售所得。總部位於賓夕法尼亞州的Vanguard集團是一家主要的投資顧問，報告稱沒有任何單一客戶持有所報告證券利益的5%以上。
Vanguard集團已向證券交易委員會(SEC)提交了修訂後的13G日程表，表明他們持有bluebird bio公司的普通股份發生了變化。截至2024年9月30日，Vanguard集團報告擁有bluebird bio公司的10,474,007股股份，佔公司普通股類別的5.40%。根據13d-1(b)規則提交的此申報顯示，Vanguard集團共享87,543股的表決權，獨立行使對10,330,825股的處置權，並額外共享143,182股的處置權。該申報顯示，Vanguard集團的客戶，包括註冊投資公司和其他託管帳戶，有權收取這些證券的分紅或出售所得。總部位於賓夕法尼亞州的Vanguard集團是一家主要的投資顧問，報告稱沒有任何單一客戶持有所報告證券利益的5%以上。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Corcept醫療
    CORT
    -- 114.220
    ABVC BioPharma
    ABVC
    -- 1.0600
    bluebird bio
    BLUE
    -- 4.880
    NLS Pharmaceutics
    NLSP
    -- 1.5400
    DBV Technologies
    DBVT
    -- 6.820
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點